APO Research, Inc.

APO RESEARCH · REPORT

Blood Coagulants

Selected research

Market Outlook & Growth Opportunities

Global Blood Coagulants Market Outlook and Growth Opportunities 2026

Market perspective

The global Blood Coagulants market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Blood Coagulants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Blood Coagulants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Blood Coagulants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Blood Coagulants market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Blood Coagulants market include Takeda, Novo Nordisk, Pfizer, Bayer, SOBI, Octapharma and CSL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Blood Coagulants market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Blood Coagulants and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Blood Coagulants sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Blood Coagulants market size, projected growth trends, production technologies, key applications, and end-use industries.

Blood Coagulants Segment by Company

Takeda

Novo Nordisk

Pfizer

Bayer

SOBI

Octapharma

CSL

Blood Coagulants Segment by Type

Recombinant Coagulation Factor

Plasma Coagulation Factor

Blood Coagulants Segment by Application

Hospital

Pharmacy

Other

Blood Coagulants Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Blood Coagulants status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Blood Coagulants market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Blood Coagulants significant trends, drivers, influence factors in global and regions.

6. To analyze Blood Coagulants competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Coagulants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Blood Coagulants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Coagulants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Blood Coagulants market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Blood Coagulants industry.

Chapter 3: Detailed analysis of Blood Coagulants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Blood Coagulants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Blood Coagulants in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Blood Coagulants Industry Trends Table 2. Blood Coagulants Industry Drivers Table 3. Blood Coagulants Industry Opportunities and Challenges Table 4. Blood Coagulants Industry Restraints Table 5. Global Blood Coagulants Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Blood Coagulants Revenue Share by Company (2021-2026) Table 7. Global Blood Coagulants Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Blood Coagulants Sales Volume Share by Company (2021-2026) Table 9. Global Blood Coagulants Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Blood Coagulants Company Ranking, (2024-2026) & (USD Million) Table 11. Global Blood Coagulants Key Company Manufacturing Base & Headquarters Table 12. Global Blood Coagulants Company, Product Type & Application Table 13. Global Blood Coagulants Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Blood Coagulants by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Recombinant Coagulation Factor Table 18. Significant Companies of Plasma Coagulation Factor Table 19. Global Blood Coagulants Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Blood Coagulants Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Blood Coagulants Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Blood Coagulants Sales Volume Share by Type (2021-2026) Table 23. Global Blood Coagulants Sales Volume Share by Type (2027-2032) Table 24. Global Blood Coagulants Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Blood Coagulants Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Blood Coagulants Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Blood Coagulants Sales Value Share by Type (2021-2026) Table 28. Global Blood Coagulants Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Blood Coagulants Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Blood Coagulants Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Blood Coagulants Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Blood Coagulants Sales Volume Share by Application (2021-2026) Table 36. Global Blood Coagulants Sales Volume Share by Application (2027-2032) Table 37. Global Blood Coagulants Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Blood Coagulants Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Blood Coagulants Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Blood Coagulants Sales Value Share by Application (2021-2026) Table 41. Global Blood Coagulants Sales Value Share by Application (2027-2032) Table 42. Global Blood Coagulants Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Blood Coagulants Sales by Region (2021-2026) & (K Units) Table 44. Global Blood Coagulants Sales Market Share by Region (2021-2026) Table 45. Global Blood Coagulants Sales by Region (2027-2032) & (K Units) Table 46. Global Blood Coagulants Sales Market Share by Region (2027-2032) Table 47. Global Blood Coagulants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Blood Coagulants Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Blood Coagulants Sales Value Share by Region (2021-2026) Table 50. Global Blood Coagulants Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Blood Coagulants Sales Value Share by Region (2027-2032) Table 52. Global Blood Coagulants Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Blood Coagulants Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Blood Coagulants Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Blood Coagulants Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Blood Coagulants Sales by Country (2021-2026) & (K Units) Table 57. Global Blood Coagulants Sales Market Share by Country (2021-2026) Table 58. Global Blood Coagulants Sales by Country (2027-2032) & (K Units) Table 59. Global Blood Coagulants Sales Market Share by Country (2027-2032) Table 60. Global Blood Coagulants Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Blood Coagulants Sales Value Market Share by Country (2021-2026) Table 62. Global Blood Coagulants Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Blood Coagulants Sales Value Market Share by Country (2027-2032) Table 64. Takeda Company Information Table 65. Takeda Business Overview Table 66. Takeda Blood Coagulants Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Takeda Blood Coagulants Product Portfolio Table 68. Takeda Recent Development Table 69. Novo Nordisk Company Information Table 70. Novo Nordisk Business Overview Table 71. Novo Nordisk Blood Coagulants Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novo Nordisk Blood Coagulants Product Portfolio Table 73. Novo Nordisk Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Blood Coagulants Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Pfizer Blood Coagulants Product Portfolio Table 78. Pfizer Recent Development Table 79. Bayer Company Information Table 80. Bayer Business Overview Table 81. Bayer Blood Coagulants Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Bayer Blood Coagulants Product Portfolio Table 83. Bayer Recent Development Table 84. SOBI Company Information Table 85. SOBI Business Overview Table 86. SOBI Blood Coagulants Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. SOBI Blood Coagulants Product Portfolio Table 88. SOBI Recent Development Table 89. Octapharma Company Information Table 90. Octapharma Business Overview Table 91. Octapharma Blood Coagulants Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Octapharma Blood Coagulants Product Portfolio Table 93. Octapharma Recent Development Table 94. CSL Company Information Table 95. CSL Business Overview Table 96. CSL Blood Coagulants Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. CSL Blood Coagulants Product Portfolio Table 98. CSL Recent Development Table 99. Key Raw Materials Table 100. Raw Materials Key Suppliers Table 101. Blood Coagulants Distributors List Table 102. Blood Coagulants Customers List Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Blood Coagulants Product Image Figure 2. Global Blood Coagulants Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Blood Coagulants Sales Value (2021-2032) & (US$ Million) Figure 4. Global Blood Coagulants Sales (2021-2032) & (K Units) Figure 5. Global Blood Coagulants Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Blood Coagulants Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Recombinant Coagulation Factor Image Figure 10. Plasma Coagulation Factor Image Figure 11. Global Blood Coagulants Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Blood Coagulants Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Blood Coagulants Sales Volume Share by Type (2021-2032) Figure 14. Global Blood Coagulants Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Blood Coagulants Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Blood Coagulants Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Blood Coagulants Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Blood Coagulants Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Blood Coagulants Sales Volume Share by Application (2021-2032) Figure 23. Global Blood Coagulants Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Blood Coagulants Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Blood Coagulants Sales Value Share by Application (2021-2032) Figure 26. Global Blood Coagulants Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Blood Coagulants Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Blood Coagulants Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Blood Coagulants Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Blood Coagulants Sales Value (2021-2032) & (US$ Million) Figure 31. North America Blood Coagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Blood Coagulants Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Blood Coagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Blood Coagulants Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Blood Coagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Blood Coagulants Sales Value (2021-2032) & (US$ Million) Figure 37. South America Blood Coagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Blood Coagulants Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Blood Coagulants Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Blood Coagulants Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Blood Coagulants Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Blood Coagulants Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Blood Coagulants Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Blood Coagulants Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Coagulation Factor
  • Plasma Coagulation Factor
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda
  • Novo Nordisk
  • Pfizer
  • Bayer
  • SOBI
  • Octapharma
  • CSL

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Blood Coagulants Sales Value (2021-2032)
  4. 1.2.2 Global Blood Coagulants Sales Volume (2021-2032)
  5. 1.2.3 Global Blood Coagulants Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Blood Coagulants Market Dynamics
  1. 2.1 Blood Coagulants Industry Trends
  2. 2.2 Blood Coagulants Industry Drivers
  3. 2.3 Blood Coagulants Industry Opportunities and Challenges
  4. 2.4 Blood Coagulants Industry Restraints
3 Blood Coagulants Market by Company
  1. 3.1 Global Blood Coagulants Company Revenue Ranking in 2025
  2. 3.2 Global Blood Coagulants Revenue by Company (2021-2026)
  3. 3.3 Global Blood Coagulants Sales Volume by Company (2021-2026)
  4. 3.4 Global Blood Coagulants Average Price by Company (2021-2026)
  5. 3.5 Global Blood Coagulants Company Ranking (2024-2026)
  6. 3.6 Global Blood Coagulants Company Manufacturing Base and Headquarters
  7. 3.7 Global Blood Coagulants Company Product Type and Application
  8. 3.8 Global Blood Coagulants Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Blood Coagulants Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Blood Coagulants Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Blood Coagulants Market by Type
  1. 4.1 Blood Coagulants Type Introduction
  2. 4.1.1 Recombinant Coagulation Factor
  3. 4.1.2 Plasma Coagulation Factor
  4. 4.2 Global Blood Coagulants Sales Volume by Type
  5. 4.2.1 Global Blood Coagulants Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Blood Coagulants Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Blood Coagulants Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Blood Coagulants Sales Value by Type
  9. 4.3.1 Global Blood Coagulants Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Blood Coagulants Sales Value by Type (2021-2032)
  11. 4.3.3 Global Blood Coagulants Sales Value Share by Type (2021-2032)
5 Blood Coagulants Market by Application
  1. 5.1 Blood Coagulants Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Blood Coagulants Sales Volume by Application
  6. 5.2.1 Global Blood Coagulants Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Blood Coagulants Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Blood Coagulants Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Blood Coagulants Sales Value by Application
  10. 5.3.1 Global Blood Coagulants Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Blood Coagulants Sales Value by Application (2021-2032)
  12. 5.3.3 Global Blood Coagulants Sales Value Share by Application (2021-2032)
6 Blood Coagulants Regional Sales and Value Analysis
  1. 6.1 Global Blood Coagulants Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Blood Coagulants Sales by Region (2021-2032)
  3. 6.2.1 Global Blood Coagulants Sales by Region: 2021-2026
  4. 6.2.2 Global Blood Coagulants Sales by Region (2027-2032)
  5. 6.3 Global Blood Coagulants Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Blood Coagulants Sales Value by Region (2021-2032)
  7. 6.4.1 Global Blood Coagulants Sales Value by Region: 2021-2026
  8. 6.4.2 Global Blood Coagulants Sales Value by Region (2027-2032)
  9. 6.5 Global Blood Coagulants Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Blood Coagulants Sales Value (2021-2032)
  12. 6.6.2 North America Blood Coagulants Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Blood Coagulants Sales Value (2021-2032)
  15. 6.7.2 Europe Blood Coagulants Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Blood Coagulants Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Blood Coagulants Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Blood Coagulants Sales Value (2021-2032)
  21. 6.9.2 South America Blood Coagulants Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Blood Coagulants Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Blood Coagulants Sales Value Share by Country, 2025 VS 2032
7 Blood Coagulants Country-level Sales and Value Analysis
  1. 7.1 Global Blood Coagulants Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Blood Coagulants Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Blood Coagulants Sales by Country (2021-2032)
  4. 7.3.1 Global Blood Coagulants Sales by Country (2021-2026)
  5. 7.3.2 Global Blood Coagulants Sales by Country (2027-2032)
  6. 7.4 Global Blood Coagulants Sales Value by Country (2021-2032)
  7. 7.4.1 Global Blood Coagulants Sales Value by Country (2021-2026)
  8. 7.4.2 Global Blood Coagulants Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Blood Coagulants Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Blood Coagulants Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Blood Coagulants Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Blood Coagulants Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Blood Coagulants Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Blood Coagulants Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Blood Coagulants Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Blood Coagulants Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Blood Coagulants Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Blood Coagulants Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Blood Coagulants Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Blood Coagulants Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Blood Coagulants Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Blood Coagulants Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Blood Coagulants Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Blood Coagulants Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Blood Coagulants Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Blood Coagulants Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Blood Coagulants Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Blood Coagulants Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Blood Coagulants Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Blood Coagulants Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Blood Coagulants Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Blood Coagulants Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Blood Coagulants Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Blood Coagulants Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Blood Coagulants Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Blood Coagulants Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Blood Coagulants Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Blood Coagulants Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Blood Coagulants Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Blood Coagulants Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Blood Coagulants Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Blood Coagulants Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Blood Coagulants Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Blood Coagulants Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Blood Coagulants Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Blood Coagulants Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Blood Coagulants Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 SOBI
  26. 8.5.1 SOBI Company Information
  27. 8.5.2 SOBI Business Overview
  28. 8.5.3 SOBI Blood Coagulants Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 SOBI Blood Coagulants Product Portfolio
  30. 8.5.5 SOBI Recent Developments
  31. 8.6 Octapharma
  32. 8.6.1 Octapharma Company Information
  33. 8.6.2 Octapharma Business Overview
  34. 8.6.3 Octapharma Blood Coagulants Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Octapharma Blood Coagulants Product Portfolio
  36. 8.6.5 Octapharma Recent Developments
  37. 8.7 CSL
  38. 8.7.1 CSL Company Information
  39. 8.7.2 CSL Business Overview
  40. 8.7.3 CSL Blood Coagulants Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CSL Blood Coagulants Product Portfolio
  42. 8.7.5 CSL Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Blood Coagulants Value Chain Analysis
  2. 9.1.1 Blood Coagulants Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Blood Coagulants Sales Mode & Process
  6. 9.2 Blood Coagulants Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Blood Coagulants Distributors
  9. 9.2.3 Blood Coagulants Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.